Canada Revises Tobacco and Vaping Products Act in 2018

Apr.07.2022
Canada revises tobacco and e-cigarette laws to protect youths and recognize vaping as a safer alternative to smoking.

The Tobacco and Vaping Products Act (TVPA) in Canada was revised in 2018, acknowledging that electronic cigarettes are a safer alternative to smoking. The revised act also includes measures to protect minors from harm caused by the product through label and promotional restrictions.

 

According to Darryl Tempest, the Government Relations Committee of the Canadian Vaping Association, electronic cigarettes have helped millions of smokers quit, and could help even more if not for the media's misleading statements and misunderstandings about the products. As part of the TVPA review process, lawmakers must have the opportunity to hear from a wide range of experts.

 

The public consultation period for the TVPA will come to a close on April 27th.

 

Meanwhile, the TVPA (Tobacco and Vaping Products Act) is set to undergo authorized parliamentary review, while the Canadian government has initiated public consultations by April 27th, 2022. A discussion paper from Health Canada encourages adult smokers to switch to safer alternatives. "For adult smokers, there appears to be a lack of awareness that e-cigarette products pose a lesser harm nicotine source for those who are currently smoking and have fully switched to e-cigarettes. A survey conducted in 2020 found that only 22% of smokers were aware that vaping is less harmful than smoking.

 

However, section 30.43 of the TVPA prohibits "making claims that are likely to lead people to believe that health benefits may result from the use of the product or its emissions or by comparing the health effects of using the product or its emissions with those of using tobacco products or their emissions. The purpose of this ban is to prevent the public from being deceived or misled regarding the health risks of using electronic cigarette products.

 

The "list of statements for promoting electronic cigarette products" from Canada's Department of Health.

 

CVA will urge Health Canada to address the issue and include relevant risk statements for licensed professional e-cigarette shops to use, based on the submitted documents. In 2018, Health Canada proposed a list of statements for promoting e-cigarette products, which has since been left dormant and stagnant within the bureaucratic structure of the department, compromising potential public health gains from smokers switching to e-cigarettes.

 

CVA looks forward to actively participating in the review process and advocating for enhanced measures to protect youth, as well as increasing information for smokers and promoting the benefits of switching to electronic cigarettes. We encourage all stakeholders to provide feedback," said Tempest.

 

(Source: Vaping Post)

 

The Tobacco and Vaping Products Act is now open for consultation in Canada. This development was reported by the Vaping Post on April 6, 2022.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Philip Morris International Announces IQOS and Devialet Collaboration at Milan Design Week 2026
Philip Morris International Announces IQOS and Devialet Collaboration at Milan Design Week 2026
Philip Morris International announced on April 20 that IQOS has partnered with French acoustic engineering company Devialet to launch “Soundsorial Design” at Milan Design Week 2026. The collaboration includes an immersive exhibition and a limited-edition product set named “Soundsorial.” The exhibition will run from April 20 to April 27 at Opificio 31 in Milan.
Apr.22 by 2FIRSTS.ai
Illicit Vape and Nicotine Pouch Seizures Concentrated in UK Hotspots, New Data Shows
Illicit Vape and Nicotine Pouch Seizures Concentrated in UK Hotspots, New Data Shows
Freedom of Information (FOI) data from the UK shows that more than 3,000 seizures of illegal nicotine products were recorded in the 2024/25 financial year, with Hull, Liverpool and Bolton emerging as the most active enforcement hotspots — highlighting that the problem of illicit vapes, nicotine pouches and smokeless tobacco products persists across many parts of the country.
Jun.16
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
FDA Center for Tobacco Products Acting Director Bret Koplow said at the American Tobacco and Nicotine Forum that the agency has reduced its premarket tobacco application backlog by about 70% over the past year and eliminated the acceptance queue. He said FDA has reviewed about 27 million applications, but only a small number have been authorized, mainly because most submissions lacked the scientific data needed to demonstrate public health benefits.
Apr.23 by 2FIRSTS.ai
Vuse Alto Adds New U.S. Price Tier as BAT Pushes Deeper Into Mass-Market Vaping
Vuse Alto Adds New U.S. Price Tier as BAT Pushes Deeper Into Mass-Market Vaping
British American Tobacco (BAT) subsidiary Vuse Alto has recently adjusted its price tiers in U.S. convenience store channels, leveraging low-cost device kits and pod promotions to reinforce its positioning in the mid-priced closed-system e-cigarette market.
Jun.17
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
CTT Pharmaceutical Holdings said it has signed a letter of intent with a U.S. company to conduct clinical trials and testing for several potential nicotine products using its patented oral thin-film technology.
Jun.18